Here are 10 Bollywood-related updates for the week August 12-19, 2026:
| # | Heading | News |
|---|---|---|
| 1 | Awarapan 2 Emerges Clear Winner Over Batwara 1947 In Independence Day Clash | On day 3, Awarapan 2’s net collection is Rs 26 crore, bringing total gross collection of India to Rs 98.10 crore, vastly outpacing Batwara 1947’s performance throughout the Independence Day weekend clash. |
| 2 | Awarapan 2 Reaches Rs 91 Crore After Four Days Of Release | Awarapan 2 has collected Rs 91 crore net in India after four days, including Rs 9.25 crore on its first Monday, maintaining strong weekday momentum against competition. |
| 3 | Batwara 1947 Struggles With Sharp Monday Drop To Rs 28.50 Crore | Batwara 1947 has reached Rs 28.50 crore net after a sharp Monday drop where it earned only Rs 2 crore, reflecting audience preference shift toward the competing Awarapan 2. |
| 4 | Emraan Hashmi’s Awarapan 2 Surpasses Lifetime Box Office Of Original Film | The film is now tracking towards an Rs 85 crore-plus opening weekend and has already surpassed the lifetime collection of the original Awarapan within days of release. |
| 5 | Independence Day Weekend Generates Combined 110 Crore Gross Box Office Surge | Combined collections from all major releases on August 15 exceeded 110 crores gross, making it among the biggest box office days of the year across Indian cinema.</cite> |
| 6 | Awarapan 2 Reviews Praise Emraan Hashmi’s Mass-Appealing Avatar And Performance | Awarapan 2 receives reviews praising Emraan Hashmi in a mass appealing avatar, with Disha Patani giving first-rate performance and the film delivering engaging emotional moments throughout. |
| 7 | Shah Rukh Khan, Ajay Devgn, Tiger Shroff Receive FDA Show-Cause Notices | Maharashtra FDA chief Tukaram Mundhe has issued notices to Shah Rukh Khan, Ajay Devgn and Tiger Shroff over a Vimal Elaichi advertisement, alleging indirect pan masala promotion. |
| 8 | Vimal Elaichi Ad Controversy Revives Akshay Kumar’s Two Thousand Twenty-Two Backlash | The latest notices revive memories of the Vimal controversy involving Akshay Kumar, who in 2022 faced intense criticism and subsequently apologised and withdrew association. |
| 9 | FDA Actors Given Fifteen Days To Explain Role And Remove Social Media Posts | The actors have been given 15 days to explain their role in the campaign and directed to discontinue association with the advertisement and remove promotional material from social media. |
| 10 | Birthday: Actor Saif Ali Khan Turns Fifty-Six Years Old Today | Bollywood star Saif Ali Khan celebrates his birthday on August 16, remaining one of Hindi cinema’s most versatile and commercially successful leading men. |
SUMMARY & INSIGHTS BY CHANDRA MOHAN:
This week revealed a box office reality that challenged every pre-release prediction about the Awarapan 2 vs Batwara 1947 clash. What began as a seemingly competitive battle resolved itself into a rout by Sunday evening — not through critical consensus, but through something more primal: audience memory and emotional investment.
Awarapan 2’s dominance, tracking toward an Rs 85 crore-plus opening weekend, isn’t merely about nostalgia, though that’s certainly part of it. It’s about Emraan Hashmi’s character occupying a distinct emotional real estate in Hindi cinema that Sunny Deol’s partition drama, despite its considerable pedigree and ensemble heft, couldn’t match. Even accounting for exhibition advantages Awarapan 2 secured, the actual audience verdict — the gap widening each day — speaks to something sociologically fascinating: audiences are choosing intimacy over spectacle, personal redemption narratives over historical grandeur.
Separately, the FDA notices to Shah Rukh Khan, Ajay Devgn and Tiger Shroff over the Vimal Elaichi advertisement represent a deeper accountability conversation in Indian advertising. What’s noteworthy isn’t the regulatory action itself, but how it forces a reckoning: brand extensions can’t indefinitely shelter a parent product’s reputation or legal constraints. The precedent here matters — it signals that star power provides no sanctuary from regulatory scrutiny when surrogate promotion allegations emerge.
